The authors also explored the other tumour biomarkers in relation to ODX-RS and found that under the combination of low and midrange ODX-RS groups, there will be 81% of node-negative patients over 50 years of age, 90% of node-positive patients, 79% among tumours with Ki-67-high (≥20%), 86% of grade 2 tumours, 70% of grade 3 tumours, 88% of patients with T3 tumours, and 82% among node-negative patients with high-risk tumours. This evidence concerns the gene MKI67 and neoplasm.